Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Dumping Agios Pharmaceuticals Inc (AGIO)

Page 1 of 2

Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed over the past few years. However, hedge funds are generally partially hedged and aim at delivering attractive risk-adjusted returns rather than following the ups and downs of equity markets hoping that they will outperform the broader market. Our research shows that hedge funds do have great stock picking skills, so let’s take a glance at the smart money sentiment towards Agios Pharmaceuticals Inc (NASDAQ:AGIO).

Agios Pharmaceuticals Inc investors should be aware of a decrease in enthusiasm from smart money recently. At the end of this article we will also compare AGIO to other stocks, including United Bankshares, Inc. (NASDAQ:UBSI), Black Stone Minerals LP (NYSE:BSM), and Fair Isaac Corporation (NYSE:FICO) to get a better sense of its popularity.

Follow Agios Pharmaceuticals Inc (NASDAQ:AGIO)
Trade (NASDAQ:AGIO) Now!

In the financial world there are dozens of indicators market participants can use to assess publicly traded companies. A couple of the less utilized indicators are hedge fund and insider trading interest. Our researchers have shown that, historically, those who follow the best picks of the elite hedge fund managers can outperform the market by a very impressive amount (see the details here).

With all of this in mind, let’s review the new action regarding Agios Pharmaceuticals Inc (NASDAQ:AGIO).

How have hedgies been trading Agios Pharmaceuticals Inc (NASDAQ:AGIO)?

Heading into Q4, a total of 9 of the hedge funds tracked by Insider Monkey were long this stock, a drop of 44% from the second quarter. With hedge funds’ positions undergoing their usual ebb and flow, there exists a few noteworthy hedge fund managers who were increasing their stakes meaningfully (or already accumulated large positions).

When looking at the institutional investors followed by Insider Monkey, Dmitry Balyasny’s Balyasny Asset Management has the number one position in Agios Pharmaceuticals Inc (NASDAQ:AGIO), worth close to $8.9 million, comprising 0.1% of its total 13F portfolio. On Balyasny Asset Management’s heels is Sabby Capital, managed by Hal Mintz, which holds a $7.7 million position; the fund has 0.3% of its 13F portfolio invested in the stock. Remaining members of the smart money that are bullish encompass Julian Baker and Felix Baker’s Baker Bros. Advisors and Cliff Asness’s AQR Capital Management.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!